ethyl N-(3-cyano-4-phenyl-1-(4-sulfamoylphenyl)-1H-pyrrol-2-yl)-formimidate | 1023885-94-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: ethyl N-(3-cyano-4-phenyl-1-(4-sulfamoylphenyl)-1H-pyrrol-2-yl)-formimidate
• CAS: 1023885-94-0
• 化学式: C₂₀H₁₈N₄O₃S
• 分子量: 394.454
• InChiKey: NCPFRXOCAZRQKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.36
• 重原子数：
  28.0
• 可旋转键数：
  6.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  110.47
• 氢给体数：
  1.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  ethyl N-(3-cyano-4-phenyl-1-(4-sulfamoylphenyl)-1H-pyrrol-2-yl)-formimidate 在 肼 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以87%的产率得到4-(3-amino-4-imino-5-phenyl-3,4-dihydropyrrolo[2,3-d]pyrimidin-7-yl)benzenesulfonamide
  参考文献：
  名称：

  Molecular modeling study and synthesis of novel pyrrolo[2,3-d]pyrimidines and pyrrolotriazolopyrimidines of expected antitumor and radioprotective activities

  摘要：

  Novel pyrrolo[2,3-d]pyrimidine derivatives 4a-e, 10, 14, 15, pyrazolopyrrolopyrimidine 13, pyrrolotriazolopyrimidine 5-9, 17 and pyrrolopyrimidotriazine 18 are reported herein. The design of these compounds was based upon the molecular modeling simulation of the fitting values and conformational energy values of the best-fitted conformers to VEGFRTK inhibitor hypothesis. This hypothesis was generated from its corresponding lead compounds using CATALYST software. The structures of these compounds were confirmed by microanalyses, IR, H-1 NMR, and mass spectral data. Compounds 6 and 15 showed interesting in vitro antitumor activity compared to doxorubicin as positive control. These results are nearly consistent with the molecular modeling studies. Docking studies were made on compound 15 to predict its binding mode. Moreover, compound 10 exhibited a significant radioprotective activity. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.11.072
• 作为产物：
  描述：

  4-(2-amino-3-cyano-4-phenypyrrol-1-yl)benzenesulfonamide 、 原甲酸三乙酯 反应 5.0h， 以75%的产率得到ethyl N-(3-cyano-4-phenyl-1-(4-sulfamoylphenyl)-1H-pyrrol-2-yl)-formimidate
  参考文献：
  名称：

  Molecular modeling study and synthesis of novel pyrrolo[2,3-d]pyrimidines and pyrrolotriazolopyrimidines of expected antitumor and radioprotective activities

  摘要：

  Novel pyrrolo[2,3-d]pyrimidine derivatives 4a-e, 10, 14, 15, pyrazolopyrrolopyrimidine 13, pyrrolotriazolopyrimidine 5-9, 17 and pyrrolopyrimidotriazine 18 are reported herein. The design of these compounds was based upon the molecular modeling simulation of the fitting values and conformational energy values of the best-fitted conformers to VEGFRTK inhibitor hypothesis. This hypothesis was generated from its corresponding lead compounds using CATALYST software. The structures of these compounds were confirmed by microanalyses, IR, H-1 NMR, and mass spectral data. Compounds 6 and 15 showed interesting in vitro antitumor activity compared to doxorubicin as positive control. These results are nearly consistent with the molecular modeling studies. Docking studies were made on compound 15 to predict its binding mode. Moreover, compound 10 exhibited a significant radioprotective activity. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.11.072